GlycoMimetics (NASDAQ:CBIO – Get Free Report) was upgraded by research analysts at Lifesci Capital to a “strong-buy” rating in a research report issued to clients and investors on Wednesday, Marketbeat Ratings reports. The brokerage presently has a $22.00 target price on the biopharmaceutical company’s stock. Lifesci Capital’s target price indicates a potential upside of 50.48% from the company’s previous close.
GlycoMimetics Stock Performance
CBIO stock opened at $14.62 on Wednesday. GlycoMimetics has a 52 week low of $11.06 and a 52 week high of $63.00. The stock has a market capitalization of $9.50 million, a P/E ratio of -0.32 and a beta of 1.62.
About GlycoMimetics
Featured Articles
- Five stocks we like better than GlycoMimetics
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Robinhood Director Sells Millions, But HOOD Stock Eyes Gains
- Earnings Per Share Calculator: How to Calculate EPS
- Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Super Micro Computer Stock’s Rally Backed by Strong Financials
Receive News & Ratings for GlycoMimetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics and related companies with MarketBeat.com's FREE daily email newsletter.
